Shore Capital reissued their hold rating on shares of GlaxoSmithKline (LON:GSK) in a research report report published on Wednesday, ThisIsMoney.Co.Uk reports.

A number of other research analysts have also commented on the company. Credit Suisse Group initiated coverage on Regeneron Pharmaceuticals in a research report on Monday, May 20th. They set a neutral rating and a $336.00 price target for the company. Goldman Sachs Group set a $13.00 price target on Ford Motor and gave the company a buy rating in a research report on Thursday, June 13th. Bryan, Garnier & Co lowered their price target on GlaxoSmithKline from GBX 1,710 ($22.34) to GBX 1,660 ($21.69) and set a neutral rating for the company in a research report on Thursday, May 2nd. Deutsche Bank reaffirmed a buy rating and set a $80.00 price target on shares of Bayerische Motoren Werke in a research report on Monday, July 8th. Finally, HSBC set a €16.50 ($19.19) price target on UniCredit and gave the company a buy rating in a research report on Tuesday, May 14th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and five have issued a buy rating to the stock. GlaxoSmithKline currently has a consensus rating of Hold and a consensus price target of GBX 1,532.32 ($20.02).

Shares of GSK stock opened at GBX 1,623.80 ($21.22) on Wednesday. The stock has a market cap of $81.00 billion and a PE ratio of 20.69. GlaxoSmithKline has a 1-year low of GBX 1,408.80 ($18.41) and a 1-year high of GBX 1,651 ($21.57). The firm’s 50-day moving average is GBX 1,584.74. The company has a debt-to-equity ratio of 942.07, a current ratio of 0.72 and a quick ratio of 0.45.

The company also recently announced a dividend, which was paid on Thursday, July 11th. Stockholders of record on Thursday, May 16th were given a GBX 19 ($0.25) dividend. This represents a dividend yield of 1.22%. The ex-dividend date was Thursday, May 16th. GlaxoSmithKline’s dividend payout ratio is currently 0.97%.

In other news, insider Manvinder Singh Banga bought 458 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was purchased at an average price of GBX 1,568 ($20.49) per share, with a total value of £7,181.44 ($9,383.82). Insiders bought a total of 482 shares of company stock valued at $755,935 in the last three months.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Recommended Story: Cost of Debt

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.